Clinical Trial Update: Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of Mexidol for Attention Deficit Hyperactivity Disorder in children aged 6-12 has completed, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Mexidol (emoxypine)

Snippet

Sponsor: Pharmasoft | Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Anxiety Disorders and Symptoms | Phase 3 | Status: COMPLETED | Results posted: 2025-08-17